Trial Profile
Relationship between contrast sensitivity, vision-related quality of life and foveal microstructure in patients with diabetic macular edema following aflibercept therapy
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Jan 2019
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 26 Dec 2018 Planned number of patients changed from 40 to 20.
- 26 Jun 2017 Status changed from not yet recruiting to recruiting.
- 23 May 2016 New trial record